La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Independence Contract a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Independence Contract..

Independence Contract (OTC:ICDI) Azioni, Catena delle Opzioni

Independence Contract Drilling Inc is engaged in providing land-based contract drilling services for oil and natural gas producers. The company constructs its own and operates a premium land rig fleet. It develops and assembles its ShaleDriller series rig which is used for the development of oil and gas properties. The company's customers for contract drilling services in the United States include oil and natural gas companies, independent oil and natural gas companies, as well as various small to mid-sized publicly traded and privately held oil and gas companies.

INDEPENDENCE CONTRCT DRLL by Independence Contract Drilling Inc

Independence Contract Drilling Inc

Piper Sandler analyst David Westenberg maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $150 to $200.

News

Price Target

Analyst Ratings

NTRA

Piper Sandler Maintains Overweight on Natera, Raises Price Target to $200

TD Cowen analyst Joshua Jennings maintains TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) with a Buy and lowers the price target from $175 to $120.

TMDX

TD Cowen Maintains Buy on TransMedics Gr, Lowers Price Target to $120

<a href="https://fortinet-2024-analyst-day.open-exchange.net/registration" title="https://fortinet-2024-analyst-day.open-exchange.net/registration">https://fortinet-2024-analyst-day.open-exchange.net/registration</a>

Events

Trading Ideas

FTNT

Watching Fortinet; Shares Spike Lower, Company Now Presenting At Its 2024 Analyst Day, 10:15am - 1:15pm ET

Former presidential candidate Robert F. Kennedy Jr. stated at <a href="https://www.benzinga.com/24/11/42028447/peanut-the-squirrel-rallies-11-as-ufc-star-jim-miller-says-justice-for-pnut-after-winning-bout">UFC 309 in New York City</a> on Saturday that a significant part of his wealth is in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
What Happened: Kennedy, who is an outspoken proponent of Bitcoin, <a href="https://x.com/TheBTCTherapist/status/1858213810055631229">shared</a> in an interview that &#8220;most&#8221; of his wealth is in Bitcoin and that he is &#8220;committed.&#8221; 
This statement follows <a href="https://www.benzinga.com/24/07/39976220/robert-kennedy-jr-proposes-bitcoin-purchase-to-match-us-gold-reserves-an-offramp-to-the-inflationary">his participation</a> in the Bitcoin Conference 2024, where he disclosed, &#8220;After attending the Bitcoin conference, I invested all my wealth in BTC.&#8221;
In a post on X on Saturday, Kennedy <a href="https://www.benzinga.com/24/11/42028576/rfk-jr-stands-firm-on-bitcoin-as-currency-of-freedom-says-howard-lutnik-as-treasury-secretary-will-be-best-for-apex-crypto">dubbed Bitcoin the "currency of freedom,"</a> emphasizing its potential as a safeguard against U.S. national debt and inflation. He also pointed to Bitcoin's ability to challenge the dollar's dominance as the global reserve currency.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42027183/michael-saylor-predicts-bitcoin-boom-says-100k-on-the-horizon">Michael Saylor Predicts Bitcoin Boom, Says $100K On The Horizon</a>
Why It Matters: Kennedy has <a href="https://x.com/RadarHits/status/1782298931092734241?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1782298931092734241%7Ctwgr%5E910df294f4deecc29e398c9b8068bd986dcadb3a%7Ctwcon%5Es1_&amp;ref_url=https%3A%2F%2Fcointelegraph.com%2Fnews%2Frfk-jr-put-us-budget-on-blockchain">consistently praised Bitcoin</a> for its role as a hedge against economic instability. 
His proposal to <a href="https://x.com/AutismCapital/status/1816949706133799165">transfer 200,000 BTC held</a> by the Department of Justice and U.S. Marshals to the U.S. Treasury demonstrates his belief in Bitcoin as a strategic asset.
He further suggested the Treasury Department begin <a href="https://x.com/AutismCapital/status/1816951410728317217">purchasing 550 BTC daily</a> to build reserves to four million BTC.
This endorsement aligns with President-elect Donald Trump picking <a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Kennedy</a> as his Secretary of Health and Human Services. 
Trump has reportedly granted Kennedy Jr. broad authority to address systemic challenges in the U.S. healthcare system but is yet to formally nominate the former Democrat for a role in his cabinet.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42033429/exclusive-binance-ceo-richard-teng-says-2025-will-outshine-2024-for-crypto">EXCLUSIVE: Binance CEO Richard Teng Says 2025 Will Outshine 2024 For Crypto</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Robert Kennedy Jr. Says 'Most' Of His Wealth Is In Bitcoin, Is 'Committed' To The 'Currency of Freedom'

Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) with a Overweight and lowers the price target from $115 to $69.

Reiteration

MRNA

Piper Sandler Reiterates Overweight on Moderna, Lowers Price Target to $69

<a href="https://esd.wa.gov/employer-requirements/layoffs-and-employee-notifications/worker-adjustment-and-retraining-notification-warn-layoff-and-closure-database" title="https://esd.wa.gov/employer-requirements/layoffs-and-employee-notifications/worker-adjustment-and-retraining-notification-warn-layoff-and-closure-database">https://esd.wa.gov/employer-requirements/layoffs-and-employee-notifications/worker-adjustment-and-retraining-notification-warn-layoff-and-closure-database</a>

Boeing To Layoff 2,199 Workers In Washington State Starting On December 20, 2024

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining by more than 100 points on Monday.
The Dow traded down 0.04% to 43,427.62 while the NASDAQ rose 0.69% to 18,809.65. The S&amp;P 500 also rose, gaining, 0.42% to 5,895.43.
Check This Out: <a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 1.5% on Monday.
In trading on Monday, information technology shares fell by 0.3%.
Top Headline
The NAHB/Wells Fargo Housing Market Index climbed to 46 in November, recording the highest reading in seven months, compared to 43 in October.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 237% to $1.02 after the company entered into an exclusive licensing deal with WY Biotech for immunotherapy development.</li>
<li>Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) got a boost, surging 17% to $5.55 after Baird upgraded the stock from Neutral to Outperform and raised its price target from $3 to $11.</li>
<li>Twist Bioscience Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) shares were also up, gaining 11% to $40.80 after the company reported better-than-expected fourth-quarter EPS and sales.</li>
</ul>
Equities Trading DOWN
<ul>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares dropped 54% to $0.7812. CareMax reached agreements to sell Management Services Organization and Core Centers&#8217; assets.</li>
<li>Shares of Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) were down 39% to $21.00 after the company announced it brought its high-dose gene therapy trial to a halt after a serious adverse event in a Rett syndrome patient.</li>
<li>IonQ, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NASDAQ">IONQ</a>) was down, falling 22% to $22.79.</li>
</ul>
Commodities In commodity news, oil traded up 2.8% to $68.88 while gold traded up 1.8% at $2,616.60.
Silver traded up 2.3% to $31.12 on Monday, while copper rose 0.4% to $4.0805.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.33%, Germany's DAX fell 0.32% and France's CAC 40 fell 0.11%. Spain's IBEX 35 Index fell 0.15%, while London's FTSE 100 rose 0.31%.
The Eurozone reported a trade surplus of €12.5 billion in September versus a year-ago surplus of €9.8 billion, compared to market expectations of €7.9 billion.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 falling 1.09%, Hong Kong's Hang Seng Index gaining 0.77%, China's Shanghai Composite Index declining 0.21%&nbsp; and India's BSE Sensex falling 0.31%.
Economics
The NAHB/Wells Fargo Housing Market Index climbed to 46 in November, recording the highest reading in seven months, compared to 43 in October.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42034108/this-technipfmc-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday">This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday</a></li>
</ul>

Equities

Eurozone

Commodities

Intraday Update

Markets

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

CMAX

HCWB

IONQ

NGNE

TWST

Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November

Piper Sandler analyst Peter Keith maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Overweight and raises the price target from $83 to $93.

Piper Sandler Maintains Overweight on Walmart, Raises Price Target to $93

Iron ore prices could remain subdued in the near future. Citi analysts see them hovering around $85 per ton by 2026, owing to incremental new supplies, rising inventories, and <a href="https://www.benzinga.com/topic/china">weak Chinese demand</a>.
&#8220;Not only has China's recent stimulus package fallen short of investor expectations, but the weekend's fresh disappointments from the inflation report and FDI data have also reinforced the view that China is still far from stabilizing its beleaguered economy,&#8221; said Hebe Chen, market analyst at IG, <a href="https://www.news.com.au/finance/business/mining/economic-tsunami-threatening-to-overwhelm-australia-after-donald-trumps-election-win/news-story/902d416fb5180b09ef457716eb39e6a7">per</a> News.com.au.
The property sector remains a significant drag on demand, with real estate investments falling by 10.1% year-on-year and new construction starts contracting by 22.2% over the same period. These challenges, coupled with growing iron ore inventories at Chinese ports — up 31% this year to nearly 150 million tons — paint the impact of a supply-demand imbalance pressuring prices. In 2025, BMI research sees iron ore averaging $100 per ton.
Geopolitical factors weigh the sentiment as Donald Trump's upcoming second term raises trade tensions. Analysts warn that rekindled tariffs could further dampen Chinese steel demand, creating additional headwinds for iron ore.
Read Next: EXCLUSIVE: <a href="https://www.benzinga.com/markets/commodities/24/11/41969513/exclusive-critical-metals-corp-advances-wolfsberg-lithium-project-unveiles-new-drilling-approval-and-saudi-plant-plans">Critical Metals Corp Advances Wolfsberg Lithium Project, Unveils New Drilling Approval and Saudi Plant Plans</a>
Finding itself between a rock and a hard place, as an important U.S. ally whose largest trading partner is China, uncertainty is pressuring the Australian mining sector. BHP Group Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHP#NYSE">BHP</a>) stock is down 20% year-to-date despite a strong recovery in September, as the market showed limited confidence in Beijing's ability to address those issues effectively.
Still, major iron ore producers, including BHP, Rio Tinto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>), Vale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>), and Fortescue (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FSUMF#OTC">FSUMF</a>), have maintained strong production levels. 
BHP achieved a record output of 260 million tons in the fiscal year ending June 2024, with guidance of 255 to 265 million tons for 2025. Rio Tinto shipped 332 million tons in 2023, projecting <a href="https://www.benzinga.com/news/earnings/24/10/41353474/rio-tinto-disappoints-on-q3-production-sets-positive-tone-about-organic-growth">323 to 338 million</a> tons in 2024. Vale increased its guidance to 323–330 million tons for 2024, while Fortescue shipped 191.6 million tons in the 2024 fiscal year and expects similar levels this year.
Simandou, the long-delayed <a href="https://www.benzinga.com/news/24/01/36544368/mining-milestone-rio-tinto-to-launch-worlds-largest-project-in-guineas-simandou-mountains">Guinean iron ore project</a>, is also expected to come online soon, adding significant new supply. Furthermore, global trends toward low-carbon steel production are reducing demand for high-grade iron ore, particularly in regions like the EU, where initiatives such as the Carbon Border Adjustment Mechanism are accelerating the shift to greener methods.
Read Next: • <a href="https://www.benzinga.com/24/11/42011906/exxon-mobil-set-to-cut-400-texas-jobs-after-pioneer-deal">Exxon Mobil To Cut 400 Texas Jobs In Stages Through 2026</a>
Photo: BJP7Images via Shutterstock

Guidance

Global

FSUMF

VALE

Analysts See Iron Ore Below $100, Weak Chinese Demand

TD Cowen analyst Andrew Kligerman maintains Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) with a Hold and lowers the price target from $444 to $419.

TD Cowen Maintains Hold on Everest Group, Lowers Price Target to $419

Piper Sandler analyst Mark Lear maintains Vital Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTLE#NYSE">VTLE</a>) with a Neutral and lowers the price target from $37 to $35.

VTLE

Piper Sandler Maintains Neutral on Vital Energy, Lowers Price Target to $35

On Monday, Twist Bioscience Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) reported a fourth-quarter loss per share of 59 cents, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss of 70 cents</a>.
Twist Bioscience&nbsp;reported fourth-quarter sales of $84.71 million, up 27% year-over-year, beating the consensus of $82.2 million and the management guidance of&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40132061/twist-bioscience-beats-q3-earnings-forecast-plans-to-achieve-50-gross-margin-by-fiscal-year-2025" rel="noreferrer noopener">$82 million–$83 million</a>.
The company shipped products to approximately 3,562 customers in fiscal 2024, compared to approximately 3,450 in 2023. Twist shipped approximately 772,000 genes in 2024 compared to approximately 634,000 genes a year ago.
Total <a href="https://investors.twistbioscience.com/static-files/8856a2ac-6031-4f11-a12e-5e169cb9621e" target="_blank" rel="noreferrer noopener">orders</a> received for the fourth quarter of fiscal 2024 grew 24% to $88.2 million compared to $71.1 million for the same period of fiscal 2023. Gross margin improved to 45.1%, up from 36.6% a year ago.
&#8220;As we head into fiscal 2025, we&#8217;re building on this momentum as we continue our final push toward achieving adjusted EBITDA breakeven while investing in research and development to deliver precision, efficiency and scalability in products and services that continue to generate profitable growth,&#8221; said&nbsp;Emily Leproust, CEO and co-founder of Twist Bioscience.
Adjusted EBITDA for the fourth quarter of fiscal 2024 was $(17.0) million compared to $(26.4) million for the same period of fiscal 2023
Guidance: Twist Bioscience expects fiscal year 2025 sales of $367 million &#8211; $377 million, up 17% &#8211; 20% year over year, <a href="https://www.benzinga.com/calendars/guidance">versus a consensus of $371.42 million.</a>
The guidance includes SynBio&#8217;s revenue guidance of approximately $142 million &#8211; $146 million, up 15% &#8211; 18%. NGS revenue of $204 million &#8211; $209 million, up 20% &#8211; 24%. Biopharma revenue is expected to be approximately $21 million &#8211; $22 million, up 5% &#8211; 8%.
The gross margin is projected to be approximately 48% for fiscal 2025, with quarterly sequential improvements and a 4QFY25 gross margin of 50%. Adjusted EBITDA of approximately $(60) million to $(65) million for fiscal 2025.
The company expects first-quarter 2025 sales of around $87 million compared to the consensus of $84.47 million.
SynBio&#8217;s revenue guidance of approximately $34 million, up 26% year over year. NGS revenue of $48 million, up 22%. Biopharma revenue is expected to be approximately $5 million. Adjusted EBITDA of approximately $(20) million with sequential improvements throughout 2025.
Price Action: TWST stock is up 12.7% at $41.59 at last check Monday.
Illustration of Phrama lab worker created with MidJourney
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/42040300/enphase-energy-powers-up-with-us-made-iq-batteries-unlocking-bonus-tax-credits" target="_blank" rel="noreferrer noopener">Enphase Energy Powers Up with US-Made IQ Batteries: Unlocking Bonus Tax Credits</a></li>
</ul>

Earnings

Health Care

Movers

General

Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps

Piper Sandler analyst Mark Lear maintains Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) with a Overweight and raises the price target from $61 to $64.

VNOM

Piper Sandler Maintains Overweight on Viper Energy, Raises Price Target to $64

In the current session, the stock is trading at $602.19, after a 0.85% increase. Over the past month, Tyler Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) stock increased by 2.88%, and in the past year, by 46.64%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1731950113_0.png" alt="Past Year Chart" />

<h3>Evaluating Tyler Technologies P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Tyler Technologies has a better P/E ratio of 109.16 than the aggregate P/E ratio of 85.49 of the Software industry. Ideally, one might believe that Tyler Technologies Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1731950113_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

A Look Into Tyler Technologies Inc's Price Over Earnings

On Saturday, Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42024655/boston-scientific-watchman-flx-left-atrial-appendage-closure-device-demonstrates-superior-bleeding" rel="noreferrer noopener">Appendage Closure (LAAC) Device</a>.
The&nbsp;WATCHMAN implant device&nbsp;is about the size of a quarter and shaped like a parachute. It is <a target="_blank" href="https://www.beaumont.org/treatments/watchman#:~:text=The%20WATCHMAN%20implant%20device%20is,forming%20and%20causing%20a%20stroke." rel="noreferrer noopener">implanted</a> into the heart to close off the left atrial appendage, a blind pouch of heart tissue to prevent blood clots from forming and causing a stroke.
Key findings from the study comparing the device to first-line oral anticoagulation (OAC) – including direct oral anticoagulants (DOAC) (95%) and warfarin (5%) – for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at the American Heart Association&#8217;s Scientific Sessions 2024 and simultaneously <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2408308" target="_blank" rel="noreferrer noopener">published</a> in &#8220;The New England Journal of Medicine.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41634450/why-is-boston-scientific-stock-trading-lower-on-wednesday" rel="noreferrer noopener">Why is Boston Scientific Stock Trading Lower On Wednesday?</a>
The trial met the primary safety endpoint of non-procedural major bleeding or clinically relevant non-major bleeding at 36 months, with the WATCHMAN FLX device demonstrating superiority to OAC (8.5% vs.18.1%)
It also met the primary efficacy endpoint of all-cause death, stroke, or systemic embolism at 36 months, with the data showing non-inferiority of the device to OAC (5.4% vs. 5.8%).
Additional findings included non-inferiority of the WATCHMAN FLX device for the combined secondary endpoint of procedural and non-procedural major bleeding at 36 months (3.9% vs. 5.0%).
The OPTION trial included 1,600 patients.
In the trial, approximately 60% of device patients had their WATCHMAN FLX implant 90-180 days following their ablation procedure. The other nearly 40% of the device patients had the two procedures performed concomitantly, with the WATCHMAN FLX implant taking place after the ablation.
In addition to the OPTION trial, the WATCHMAN technology is being evaluated against DOAC as first-line therapy in lower-risk patients within the CHAMPION-AF randomized trial.
The latest-generation WATCHMAN FLX Pro LAAC Device was approved in the U.S. in 2023. It is similarly being studied in several clinical trials.
Price Action: BSX stock is up 4.36% at $90.79 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42038673/netflix-scores-big-beyonce-set-to-headline-nfl-christmas-halftime-show" target="_blank" rel="noreferrer noopener">Netflix Scores Big: Beyoncé Set To Headline NFL Christmas Halftime Show</a></li>
</ul>
Image: Shutterstock

Large Cap

Why Is Medical Device Giant Boston Scientific Stock Trading Higher On Monday?

QMMM

QMMM Holdings Shares Halted On Circuit Breaker, Stock Now Down -65.1%

Piper Sandler analyst Mark Lear maintains Sitio Royalties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STR#NYSE">STR</a>) with a Overweight and raises the price target from $27 to $28.

Piper Sandler Maintains Overweight on Sitio Royalties, Raises Price Target to $28

HCW Biologics Shares Resume Trading

WIIM

DWTX

Dogwood Therapeutics shares are trading lower. The company announced top line data from the recently completed BHC IMC-2 Long-COVID study.

Roblox Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) announced new tools today designed to enhance safety for its young user base, which includes a significant number of children. These updates allow parents to remotely manage their child's account, view their friends list, and set <a href="https://www.benzinga.com/general/gaming">limits on playtime.</a>
Starting today, Roblox is simplifying its content labeling system and restricting games and experiences available to children under nine by default. In the coming months, additional measures will limit users under 13 from directly messaging others outside games and restrict in-game communication to public messages only.
See Also:<a href="https://www.benzinga.com/general/gaming/24/10/41255828/roblox-denies-hindenburgs-accusations-of-inflating-metrics-failing-at-child-safety-calls-them-misl"> Roblox Denies Hindenburg&#8217;s Accusations Of Inflating Metrics, Failing At Child Safety — Calls Them &#8216;Misleading&#8217;</a>
"We've spent nearly two decades building strong safety systems, but we know there's always more to be done," <a href="https://corp.roblox.com/newsroom/2024/11/major-updates-to-our-safety-systems-and-parental-controls">said </a>Matt Kaufman, Roblox's chief safety officer. "Last quarter saw a record average for daily active users on Roblox—over 88 million—and as our platform has grown in scale, we have always recognized that our approach to safety must evolve with it. Today's launch represents the next stage in that evolution."
These changes follow <a href="https://www.benzinga.com/news/24/11/41819699/roblox-tightens-safety-bans-preteens-from-virtual-social-spaces">recent updates</a> requiring parental permission for children to use some in-game chat features and banning social hangout experiences for users under 13. Roblox attributed the latter decision to "user behavior that can potentially pose a risk."
<h3 class="wp-block-heading">Ongoing Safety Concerns</h3>
Roblox has faced criticism over its handling of safety on the platform. A Bloomberg <a href="https://www.bloomberg.com/features/2024-roblox-pedophile-problem/">report </a>earlier this year revealed 13,316 instances of child exploitation reported by Roblox in 2023, with over two dozen arrests resulting from in-game interactions. 
In response, Roblox says it has consulted experts from organizations such as the National Association for Media Literacy Education (NAMLE) and the Family Online Safety Institute (FOSI) to develop these new safety features. 
The company noted that these updates stem from internal research involving surveys with parents and children and input from child safety organizations.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/41996480/1-8-million-instances-of-hate-content-on-steam-is-valve-ignoring-extremism-report">1.8 Million Instances Of Hate Content On Steam — Is Valve Ignoring Extremism?: Report</a></li>
</ul>
Image credits: Shutterstock.

Comments

Independence Contract

Independence Contract (ICDI) Opzioni

Independence Contract (OTC:ICDI) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO